TL;DR:
- Ryght introduces GenAI platform for life science companies.
- The platform focuses on security and accelerates scientific research, clinical operations, and commercialization.
- It offers a cost-effective alternative to internal development, making GenAI accessible to a wider range of companies.
- BEK Health partners with Ryght to integrate GenAI capabilities into patient-matching software.
Main AI News:
In a significant move towards revolutionizing the life science industry, Ryght, a pioneer in generative AI (GenAI) technology, has officially launched its groundbreaking platform, Ryght. With a steadfast focus on security, Ryght is an enterprise-grade solution that empowers life science companies to develop and implement GenAI applications within the confines of their organizations. Leveraging the wealth of knowledge derived from biomedical literature and an ever-expanding repository of medical records, Ryght expedites scientific research, enhances clinical operations, and accelerates commercialization efforts, delivering actionable insights and well-informed decision-making to the life science sector.
The traditional approach of many companies involved investing in internal development teams to experiment with building GenAI applications for their workforce, incurring substantial costs exceeding $2 million annually. This financial burden, coupled with the diversion of valuable time and resources away from core mission-related projects, places such initiatives beyond the reach of most organizations. Ryght emerges as a viable alternative, offering life science companies the opportunity to seamlessly integrate adaptable GenAI solutions into their day-to-day operations, thereby streamlining workflows and fostering innovation.
Simon Arkell, the CEO of Ryght, emphasized, “Ryght sets a new standard for enterprise-grade GenAI solutions, combining security and ease of deployment across life science entities of all sizes. It facilitates secure querying of proprietary data and documents in various standard formats. Moreover, our dedicated team stands ready to develop and implement tailor-made applications that seamlessly integrate with a company’s unique data streams and align with specific industry requirements. We eagerly anticipate collaborating with companies to create streamlined operations, freeing up valuable time and resources for innovation within the life science sector.”
Furthermore, a momentous partnership has been forged between BEK Health and Ryght, aimed at co-developing applications that harness Ryght’s cutting-edge GenAI capabilities to enhance the BEKHealth AI-powered patient-matching software platform. Dave Levin, the CEO of BEKHealth, expressed his excitement about the collaboration, stating, “We are thrilled to join forces with Ryght and harness the power of their GenAI platform and expertise. Ryght’s state-of-the-art technology seamlessly aligns with our commitment to innovation, enabling us to swiftly identify clinically qualified patients and expedite enrollment in clinical research. Through the utilization of AI, we anticipate unlocking novel insights and accelerating access to critical clinical research.”
Conclusion:
Ryght’s GenAI platform, with its emphasis on security and cost-effectiveness, is poised to transform the life science industry. It provides a scalable solution for companies to harness GenAI’s potential, ultimately fostering innovation and efficiency within the sector. The partnership with BEK Health signifies the growing importance of AI in accelerating clinical research and patient care, making it a significant development to watch in the market.
